Neurodegenerative disorders represent a high societal burden impacting patients, their families, and public healthcare systems. Patients with a neurodegenerative disorder frequently display at least one comorbidity, which together with the observed polypharmacy creates a highly complex system that needs better understanding to optimise current care pathways. Recent developments give grounds for cautious optimism that a disease-modifying therapy is on the horizon.
Opinion Article by Derrick Measham, Head of Research and Development, Cloud Telephony Specialist X-on.The problem was spelled out in Dr Claire Fuller's 'Stocktake' for NHS England in May, which reported that "there are real signs of genuine and growing discontent with primary care - both from the public who use it and from the professionals who work within it."
Precision medicine, a technology still in its infancy, is an approach to treatment that uses information about an individual's medical history and genetic profile and relates it to the information of many others to find patterns that can help prevent, diagnose or treat a disease.
The work was pioneered by Dr Tuan-Khoa Nguyen, Professor Nam-Trung Nguyen and Dr Hoang-Phuong Phan (currently a senior lecturer at the University of New South Wales) from Griffith University's Queensland Micro and Nanotechnology Centre (QMNC) using in-house silicon carbide technology as a new platform for long-term electronic biotissue interfaces.
The Multicentre Epilepsy Lesion Detection project (MELD) used over 1,000 patient MRI scans from 22 global epilepsy centres to develop the algorithm,
| Location: | Multiple locations |
| Job Type: | Full-Time |
| Employer: | Siemens Healthineers |